IGES Journal Club

Get information about upcoming meetings from Twitter (@genepisociety) or Facebook (International Genetic Epidemiology Society)


Next Journal Club Meeting

"The All of Us Research Program Data Resources and Access"
April 15th 2024. 12 pm (EDT), 9 am (PDT) and 6 pm (CEST), 5pm (BST)

Register here: https://utoronto.zoom.us/meeting/register/tZcsce6orzkpG9EgYch-bkIkmDuN4UAfaFnh

Presenter: Dr. Anji Musick, Director of the Scientific Data Strategy Branch, Division of Medical and Scientific Research, National Institutes of Health, US.

The All of Us Research Program is a historic effort to partner with at least 1 million people across the United States to build one of the most diverse biomedical data resources of its kind, which researchers can use to gain insights into the biological, environmental, and behavioral factors that influence health. By design, All of Us supports broad data access, a core value of the program, to help advance research that ultimately will further our understanding of health, improve health equity, and lead to more tailored approaches of disease prevention and treatment.

The National Institutes of Health’s All of Us Research Program is now taking applications from international academic, not-for-profit, and health care organizations to access data through its Researcher Workbench.

https://allofus.nih.gov/news-events/announcements/all-us-research-program-updates-data-use-eligibility-propel-precision-medicine

 

Speaker bio:

Dr. Anjené (Anji) Musick is the Director of the Scientific Data Strategy Branch in the Division of Medical and Scientific Research in the National Institutes of Health All of Us Research Program, charged with maximizing the scientific integrity of research data collected on or donated by All of Us participants to achieve the broadest impact for biomedical discovery. She is also the Genomics Lead for All of Us, leading all genomic data production pipelines, workflows, and curation for release to researchers in the All of Us Research Hub. She also serves as Chair of the All of Us Regulatory Compliance Committee overseeing the FDA Investigational Device Exemption obtained by All of Us to ethically and responsibly return medically actionable genetic results directly to participants.

Dr. Musick has been at the NIH for over 20 years, starting as a pre-doctoral intramural research training fellow at the National Human Genome Research Institute in 1995 where she conducted research on the molecular genetics of type 2 diabetes in Francis Collins’ laboratory. She then returned to NIH in 2002 as an intramural staff scientist, where she led the genetics research program in the Child Psychiatry Branch in the National Institute of Mental Health (NIMH), primarily focusing on the genetics of childhood onset schizophrenia and other severe neurodevelopmental disorders.  In 2012, Dr. Musick transitioned to the extramural program at NIMH as a program director for the Genetics of Mental Illness and Genetic Epidemiology Programs and subsequently served as the Branch Chief of the Genomics Research Branch in the Division of Neuroscience and Basic Behavioral Science from 2015 – 2020.

Dr. Musick received her B.A. in psychology from the University of Virginia, her M.P.H. and Ph.D. in genetic epidemiology in genetics from the Johns Hopkins Bloomberg School of Public Health.

 

 

 

 

Papers discussed during 2022:

Presenter: Mafalda Figueiredo Dias
Paper title: Disease variant prediction with deep generative models of evolutionary data

Presenter: Scott Ritchie
Paper title: Integrative analysis of the plasma proteome and polygenic risk of cardiometabolic diseases

Presenter: Sharon Lutz
Paper title: Caution against examining the role of reverse causality in Mendelian Randomization

Presenters: Farhad Hormozdiari and Cory McLean
Paper title: DeepNull models non-linear covariate effects to improve phenotypic prediction and association power

Presenter: Jenna Ballard
Paper title: Shared components of heritability across genetically correlated traits

Presenter: Ying Wang
Paper title: Global biobank analyses provide lessons for computing polygenic risk scores across diverse cohorts